Evidence map›Paper›PMID 29596317›Full record

ArticleInternational journal of molecular sciences2018

Distribution of Glutathione-Stabilized Gold Nanoparticles in Feline Fibrosarcomas and Their Role as a Drug Delivery System for Doxorubicin-Preclinical Studies in a Murine Model.

Katarzyna Zabielska-Koczywąs, Anna Wojtalewicz, Ewelina Użarowska, Agata Klejman, Agata Wojtkowska, Izabella Dolka, Marek Wojnicki, Katarzyna Sobczak, Michał Wójcik, Haifa Shen and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Katarzyna Zabielska-KoczywąsDepartment of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-787 Warsaw, Poland. katarzyna_zabielska@sggw.pl.ORCID 0000-0003-1691-3982
Anna WojtalewiczDepartment of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-787 Warsaw, Poland. aniawojt@hotmail.com.
Ewelina UżarowskaLaboratory of Animal Models, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura 3, 02-093 Warsaw, Poland. e.uzarowska@nencki.gov.pl.
Agata KlejmanLaboratory of Animal Models, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura 3, 02-093 Warsaw, Poland. agata.klejman@gmail.com.
Agata WojtkowskaDepartment of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-787 Warsaw, Poland. agata_wet@interia.pl.
Izabella DolkaDepartment of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159, 02-787 Warsaw, Poland. izabella_dolka@sggw.pl.
Marek WojnickiFaculty of Non-Ferrous Metals, AGH University of Science and Technology, Mickiewicza 30, 30-059 Kraków, Poland. marekw@agh.edu.pl.
Katarzyna SobczakFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland. katarzynasobczak@student.uw.edu.pl.
Michał WójcikFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland. mwojcik@chem.uw.edu.pl.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, 6670 Bertner Ave., Houston, TX 77030, USA. hshen@houstonmethodist.org.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, 6670 Bertner Ave., Houston, TX 77030, USA. mferrari@houstonmethodist.org.
Roman LechowskiDepartment of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-787 Warsaw, Poland. roman_lechowski@sggw.pl.
Warsaw University of Life Sciences · PLHouston Methodist · USInstytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLUniversity of Warsaw · PLAGH University of Krakow · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Feline injection site sarcomas (FISS) are malignant skin tumors with high recurrence rates despite the primary treatment of radical surgical resections. Adjunctive radiotherapy or chemotherapy with doxorubicin is mostly ineffective. Cellular and molecular causes of multidrug resistance, specific physio-chemical properties of solid tumors impairing drug transport, and the tumor microenvironment have been indicated for causing standard chemotherapy failure. Gold nanoparticles are promising imaging tools, nanotherapeutics, and drug delivery systems (DDS) for chemotherapeutics, improving drug transport within solid tumors. This study was conducted to assess the distribution of 4-nm glutathione-stabilized gold nanoparticles in FISS and their influence on kidney and liver parameters in nude mice. The role of gold nanoparticles as a doxorubicin DDS in FISS was examined to determine the potential reasons for failure to translate results from in vitro to in vivo studies. Grade III tumors characterized by a large area of necrosis at their core displayed positive immuneexpression of tumor-associated macrophages (TAM) at both the periphery and within the tumor core near the area of necrosis. Gold nanoparticles did not cause necrosis at the injection site and had no negative effect on liver and kidney parameters in nude mice. Gold nanoparticles accumulated in the tumor core and at the periphery and co-internalized with TAM-an important observation and potential therapeutic target warranting further investigation. The large area of necrosis and high immunoexpression of TAM, indicating "pro-tumor macrophages", may be responsible for FISS tumor progression and therapeutic failure. However, further studies are required to test this hypothesis.

Indexed as

Antibiotics, AntineoplasticDoxorubicinGlutathioneGoldMetal NanoparticlesSarcomaSkin NeoplasmsAnimalsCell Line, TumorDrug Delivery SystemsMiceMice, NudeXenograft Model Antitumor AssaysAntibiotics, AntineoplasticDoxorubicinGlutathioneGoldcatsconfocal microscopydoxorubicinfibrosarcomagold nanoparticlesICP-MSKi-67murine modeltumor-associated macrophages

Identifiers

PMID29596317
PMCPMC5979397
OpenAlexW2795304638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.